Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

By S. Black, H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. Hansen, L. Elvin, K. Ensor, J. Hackell, G. Siber and 7 more. The Pediatric Infectious Disease Journal, 2000

2,244 citations recorded by the source corpus.

Subfields: Epidemiology, Otorhinolaryngology

View Paper: https://www.semanticscholar.org/paper/47526a051f2c1e0a53865a52ba2f2211a13b1032

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Julian Parkhill
2. Jonathan A. McCullers

Citations in the corpus

• Genetic Analysis of the Capsular Biosynthetic Locus from All 90 Pneumococcal Serotypes (2006, background): “conjugated polysaccharide vaccine has been introduced and shown to be highly effective [7,8].”
• Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia (2002, methodology): “10 The Wyeth heptavalent pneumococcal conjugate vaccine (PCV) has been shown to be safe, immunogenic and effective in preventing invasive disease.(1) We report here on an evaluation of the effectiveness of this vaccine against pneumonia in the same study population.”
• Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis (2010, background): “An initial multicenter, controlled, double-blind study examined the efficacy of the heptavalent pneumococcal conjugate vaccine (coupled to the protein carrier CRM197) administered in 4 doses (2, 4, 6, and 12 to 15 months of age) to 37,868 infants and children (33).”